A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus

Vaccine

Volumn 26, Issue 20, 2008, Pages 2471-2481

  Martin, Perrine ^a   Simon, Benjamin ^b   Lone, Yu Chun ^c   Chatel, Laurence ^a   Barry, Ronald ^b   Inchauspé, Geneviève ^a   Fournillier, Anne ^a  

^a Healthy Pigs Production and Experimentation Section   (France)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c INSERM   (France)

Author keywords

HCV; IFNgamma; Minigenes; T lymphocytes; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; EPITOPE; HEPATITIS C VACCINE; MINIGENE VACCINE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4; NONSTRUCTURAL PROTEIN 5B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; ENDOPLASMIC RETICULUM; ENZYME LINKED IMMUNOSPOT ASSAY; GENE SEQUENCE; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RNA TRANSLATION; T LYMPHOCYTE ACTIVATION;

ADENOVIRIDAE; ANIMALS; COLONY COUNT, MICROBIAL; EPITOPES; GENETIC VECTORS; HEPACIVIRUS; INTERFERON TYPE II; LISTERIA; LIVER; MICE; MICE, TRANSGENIC; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; VACCINES, SYNTHETIC; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 43049144208     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.028     Document Type: Article

References (51)

1. Alexander J., Oseroff C., Dahlberg C., Qin M., Ishioka G., Beebe M., et al. A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. J Immunol 168 12 (2002) 6189-6198
2. Baldridge J.R., Barry R.A., and Hinrichs D.J. Expression of systemic protection and delayed-type hypersensitivity to Listeria monocytogenes is mediated by different T-cell subsets. Infect Immun 58 3 (1990) 654-658
3. Battegay M., Fikes J., Di Bisceglie A.M., Wentworth P.A., Sette A., Celis E., et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 69 4 (1995) 2462-2470
4. Bowen D.G., and Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 7053 (2005) 946-952
5. Brinster C., Muguet S., Lone Y.C., Boucreux D., Renard N., Fournillier A., et al. Different hepatitis C virus nonstructural protein 3 (NS3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology 34 6 (2001) 1206-1217
6. Capone S., Zampaglione I., Vitelli A., Pezzanera M., Kierstead L., Burns J., et al. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J Immunol 177 10 (2006) 7462-7471
7. Chang K.M., Gruener N.H., Southwood S., Sidney J., Pape G.R., Chisari F.V., et al. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol 162 2 (1999) 1156-1164
8. Chang K.M., Rehermann B., McHutchison J.G., Pasquinelli C., Southwood S., Sette A., et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 100 9 (1997) 2376-2385
9. Cox A.L., Mosbruger T., Lauer G.M., Pardoll D., Thomas D.L., and Ray S.C. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 42 1 (2005) 104-112
10. Day C.L., Lauer G.M., Robbins G.K., McGovern B., Wurcel A.G., Gandhi R.T., et al. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol 76 24 (2002) 12584-12595
11. Diepolder H.M., Gerlach J.T., Zachoval R., Hoffmann R.M., Jung M.C., Wierenga E.A., et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 71 8 (1997) 6011-6019
12. Doolan D.L., Southwood S., Chesnut R., Appella E., Gomez E., Richards A., et al. HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J Immunol 165 2 (2000) 1123-1137
13. Duraiswamy J., Sherritt M., Thomson S., Tellam J., Cooper L., Connolly G., et al. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 101 8 (2003) 3150-3156
14. Dustin L.B., and Rice C.M. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 25 (2007) 71-99
15. Firat H., Tourdot S., Ureta-Vidal A., Scardino A., Suhrbier A., Buseyne F., et al. Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H- 2 class I KO mice. Eur J Immunol 31 10 (2001) 3064-3074
16. Fournillier A., Dupeyrot P., Martin P., Parroche P., Pajot A., Chatel L., et al. Potent induction of T-cell mediated responses following in vitro and in vivo vaccination with hepatitis C virus multiepitope long peptides. Vaccine 24 16 (2006) 3153-3164
17. Frelin L., Ahlen G., Alheim M., Weiland O., Barnfield C., Liljestrom P., et al. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. Gene Ther 11 6 (2004) 522-533
18. Golovina T.N., Wherry E.J., Bullock T.N., and Eisenlohr L.C. Efficient and qualitatively distinct MHC class I-restricted presentation of antigen targeted to the endoplasmic reticulum. J Immunol 168 6 (2002) 2667-2675
19. Hakamada T., Funatsuki K., Morita H., Ugajin T., Nakamura I., Ishiko H., et al. Identification of novel hepatitis C virus-specific cytotoxic T lymphocyte epitopes by ELISpot assay using peptides with human leukocyte antigen-A*2402-binding motifs. J Gen Virol 85 Pt 6 (2004) 1521-1531
20. Himoudi N., Abraham J.D., Fournillier A., Lone Y.C., Joubert A., Op De Beeck A., et al. Comparative vaccine studies in HLA-A2.1 transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J Virol 76 24 (2002) 12735-12746
21. Hoofnagle J.H., and Seeff L.B. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 355 23 (2006) 2444-2451
22. Huang Z., Murray M.G., and Secrist III J.A. Recent development of therapeutics for chronic HCV infection. Antiviral Res 71 2-3 (2006) 351-362
23. Iglesias M.C., Mollier K., Beignon A.S., Souque P., Adotevi O., Lemonnier F., et al. Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. Mol Ther 15 6 (2007) 1203-1210
24. Kato N., Hijikata M., Ootsuyama Y., Nakagawa M., Ohkoshi S., Sugimura T., et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 87 24 (1990) 9524-9528
25. Lauer G.M., Barnes E., Lucas M., Timm J., Ouchi K., Kim A.Y., et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastro 127 3 (2004) 924-936
26. Lechner F., Wong D.K., Dunbar P.R., Chapman R.T., Chung R.T., Dohrenwend P., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191 (2000) 1499-1512
27. Lorin C., Delebecque F., Labrousse V., Da Silva L., Lemonnier F., Brahic M., et al. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes. Vaccine 23 36 (2005) 4463-4472
28. Martin P., Parroche P., Chatel L., Barretto C., Beck A., Trepo C., et al. Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen. J Med Virol 74 3 (2004) 397-405
29. Martin P., and Inchauspe G. Hepatitis C vaccines. Drug Discov Today: Therap Strategies 3 2 (2006) 203-209
30. Mateo L., Gardner J., Chen Q., Schmidt C., Down M., Elliott S.L., et al. An HLA-A2 polyepitope vaccine for melanoma immunotherapy. J Immunol 163 7 (1999) 4058-4063
31. Meunier J.C., Engle R.E., Faulk K., Zhao M., Bartosch B., Alter H., et al. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci USA 102 12 (2005) 4560-4565
32. Minev B.R., Chavez F.L., Dudouet B.M., and Mitchell M.S. Synthetic insertion signal sequences enhance MHC class I presentation of a peptide from the melanoma antigen MART-1. Eur J Immunol 30 8 (2000) 2115-2124
33. Narum D.L., Kumar S., Rogers W.O., Fuhrmann S.R., Liang H., Oakley M., et al. Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect Immun 69 12 (2001) 7250-7253
34. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., and Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185 12 (1997) 2043-2051
35. Pestka J.M., Zeisel M.B., Blaser E., Schurmann P., Bartosch B., Cosset F.L., et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 104 14 (2007) 6025-6030
36. Ramakrishna L., Anand K.K., Mohankumar K.M., and Ranga U. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization. J Virol 78 17 (2004) 9174-9189
37. Saric T., Chang S.C., Hattori A., York I.A., Markant S., Rock K.L., et al. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol 3 12 (2002) 1169-1176
38. Selby M., Erickson A., Dong C., Cooper S., Parham P., Houghton M., et al. Hepatitis C virus envelope glycoprotein E1 originates in the endoplasmic reticulum and requires cytoplasmic processing for presentation by class I MHC molecules. J Immunol 162 2 (1999) 669-676
39. Serwold T., Gonzalez F., Kim J., Jacob R., and Shastri N. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 419 6906 (2002) 480-483
40. Simon B.E., Cornell K.A., Clark T.R., Chou S., Rosen H.R., and Barry R.A. DNA vaccination protects mice against challenge with Listeria monocytogenes expressing the hepatitis C virus NS3 protein. Infect Immun 71 11 (2003) 6372-6380
41. Smyk-Pearson S., Tester I.A., Lezotte D., Sasaki A.W., Lewinsohn D.M., and Rosen H.R. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. J Infect Dis 194 4 (2006) 454-463
42. Subbramanian R.A., Kuroda M.J., Charini W.A., Barouch D.H., Costantino C., Santra S., et al. Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys. J Virol 77 18 (2003) 10113-10118
43. Sundaram R., Sun Y., Walker C.M., Lemonnier F.A., Jacobson S., and Kaumaya P.T. A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A*0201 transgenic mice: implications for HTLV-1 vaccine design. Vaccine 21 21-22 (2003) 2767-2781
44. Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C., and Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194 10 (2001) 1395-1406
45. Tine J.A., Firat H., Payne A., Russo G., Davis S.W., Tartaglia J., et al. Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes. Vaccine 23 8 (2005) 1085-1091
46. Vertuani S., Bazzaro M., Gualandi G., Micheletti F., Marastoni M., Fortini C., et al. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur J Immunol 32 1 (2002) 144-154
47. Wilson C.C., Palmer B., Southwood S., Sidney J., Higashimoto Y., Appella E., et al. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J Virol 75 9 (2001) 4195-4207
48. Wong D.K., Dudley D.D., Afdhal N.H., Dienstag J., Rice C.M., Wang L., et al. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol 160 3 (1998) 1479-1488
49. Woodberry T., Gardner J., Mateo L., Eisen D., Medveczky J., Ramshaw I.A., et al. Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes. J Virol 73 7 (1999) 5320-5325
50. Xu W., Chu Y., Zhang R., Xu H., Wang Y., and Xiong S. Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine. Virology 334 2 (2005) 255-263
51. Yadava A., and Ockenhouse C.F. Effect of codon optimization on expression levels of a functionally folded malaria vaccine candidate in prokaryotic and eukaryotic expression systems. Infect Immun 71 9 (2003) 4961-4969